CL2018001612A1 - Método de terapia fotodinámica (pdt) para el cáncer de vejiga - Google Patents

Método de terapia fotodinámica (pdt) para el cáncer de vejiga

Info

Publication number
CL2018001612A1
CL2018001612A1 CL2018001612A CL2018001612A CL2018001612A1 CL 2018001612 A1 CL2018001612 A1 CL 2018001612A1 CL 2018001612 A CL2018001612 A CL 2018001612A CL 2018001612 A CL2018001612 A CL 2018001612A CL 2018001612 A1 CL2018001612 A1 CL 2018001612A1
Authority
CL
Chile
Prior art keywords
bladder cancer
photodynamic therapy
pdt
therapy method
composition
Prior art date
Application number
CL2018001612A
Other languages
English (en)
Spanish (es)
Inventor
Kjetil Hestdal
Aslak Godal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of CL2018001612A1 publication Critical patent/CL2018001612A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/307—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the urinary organs, e.g. urethroscopes, cystoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CL2018001612A 2015-12-17 2018-06-14 Método de terapia fotodinámica (pdt) para el cáncer de vejiga CL2018001612A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15200938 2015-12-17

Publications (1)

Publication Number Publication Date
CL2018001612A1 true CL2018001612A1 (es) 2019-01-11

Family

ID=55066354

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001612A CL2018001612A1 (es) 2015-12-17 2018-06-14 Método de terapia fotodinámica (pdt) para el cáncer de vejiga

Country Status (18)

Country Link
US (2) US11235168B2 (cg-RX-API-DMAC7.html)
EP (1) EP3389716B1 (cg-RX-API-DMAC7.html)
JP (1) JP6995755B2 (cg-RX-API-DMAC7.html)
KR (1) KR102787192B1 (cg-RX-API-DMAC7.html)
CN (2) CN108697800A (cg-RX-API-DMAC7.html)
AU (1) AU2016372575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018011965A2 (cg-RX-API-DMAC7.html)
CA (1) CA3008552C (cg-RX-API-DMAC7.html)
CL (1) CL2018001612A1 (cg-RX-API-DMAC7.html)
DK (1) DK3389716T3 (cg-RX-API-DMAC7.html)
ES (1) ES2910034T3 (cg-RX-API-DMAC7.html)
IL (1) IL259925B (cg-RX-API-DMAC7.html)
MX (1) MX385912B (cg-RX-API-DMAC7.html)
PL (1) PL3389716T3 (cg-RX-API-DMAC7.html)
RU (1) RU2745194C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201805000RA (cg-RX-API-DMAC7.html)
WO (1) WO2017103285A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804530B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697800A (zh) * 2015-12-17 2018-10-23 光治疗Asa公司 用于膀胱癌的光动力疗法（pdt）的方法
CN110420326A (zh) * 2019-09-17 2019-11-08 上海复旦张江生物医药股份有限公司 一种多替泊芬的应用
CA3219438A1 (en) * 2021-08-17 2023-02-23 Boston Scientific Scimed, Inc. Devices, systems, and methods for activation of a photoactive agent
KR20250154511A (ko) 2023-03-07 2025-10-28 포토큐어 에이에스에이 방광암 치료

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
DE122006000051I2 (de) 1995-03-10 2010-07-08 Photocure Asa Hoffsveien 48 Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie
US20050003154A1 (en) * 2002-12-13 2005-01-06 White Gary L. Laminated building panels having preselected colors
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
GB0700580D0 (en) 2007-01-11 2007-02-21 Photocure Asa Use
GB0724279D0 (en) 2007-12-12 2008-01-23 Photocure Asa Use
CN101891639A (zh) 2009-05-20 2010-11-24 上海先导化学有限公司 一种制备5-氨基酮戊酸盐酸盐的方法
WO2010142456A1 (en) 2009-06-11 2010-12-16 Photocure Asa Solid compositions comprising 5-aminolevulinic acid
RU2526803C2 (ru) 2009-06-11 2014-08-27 ФотоКьюэр АСА Полутвердые композиции и фармацевтические продукты
RU2448745C2 (ru) * 2010-05-31 2012-04-27 Олег Феликсович Каган Способ лечения поверхностного рака мочевого пузыря
CN104244804B (zh) 2011-12-19 2017-04-26 丹麦科技大学 用于内窥镜应用的照明系统
AU2013298525B2 (en) * 2012-08-03 2017-12-14 Photocure Asa Compounds
GB201221123D0 (en) * 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
CN108697800A (zh) * 2015-12-17 2018-10-23 光治疗Asa公司 用于膀胱癌的光动力疗法（pdt）的方法

Also Published As

Publication number Publication date
US20190022404A1 (en) 2019-01-24
BR112018011965A2 (pt) 2018-12-04
SG11201805000RA (en) 2018-07-30
EP3389716A1 (en) 2018-10-24
IL259925A (en) 2018-07-31
CA3008552A1 (en) 2017-06-22
IL259925B (en) 2022-04-01
RU2018123834A3 (cg-RX-API-DMAC7.html) 2020-04-13
AU2016372575B2 (en) 2022-12-08
CN108697800A (zh) 2018-10-23
PL3389716T3 (pl) 2022-06-20
US20220152411A1 (en) 2022-05-19
US11980772B2 (en) 2024-05-14
US11235168B2 (en) 2022-02-01
KR102787192B1 (ko) 2025-03-25
ZA201804530B (en) 2019-09-25
AU2016372575A1 (en) 2018-07-12
MX385912B (es) 2025-03-18
KR20180094986A (ko) 2018-08-24
RU2018123834A (ru) 2020-01-17
CA3008552C (en) 2024-01-02
NZ743697A (en) 2024-10-25
ES2910034T3 (es) 2022-05-11
DK3389716T3 (da) 2022-04-11
WO2017103285A1 (en) 2017-06-22
CN119345612A (zh) 2025-01-24
JP2019501161A (ja) 2019-01-17
RU2745194C2 (ru) 2021-03-22
EP3389716B1 (en) 2022-03-23
JP6995755B2 (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
CL2020000299A1 (es) Compuestos, composiciones y métodos.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2015011296A (es) Dispositivo foto-terapeutico, metodo y uso.
MX2015017312A (es) Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
CL2018001612A1 (es) Método de terapia fotodinámica (pdt) para el cáncer de vejiga
MX383484B (es) Método para tratar el cáncer.
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma